Aphria: $16.4 million In a distant third, but growing very rapidly, is Canada's Aphria (NASDAQOTH: APHQF), which produced $16.4 million in full-year sales for fiscal 2017. Every headline figure moved in the right direction for Aphria in its latest full-year report, including 142% sales growth, 962% EBITDA (earnings before interest, taxes, depreciation, and amortization) growth from the previous year, a 44% decline in cash costs to produce dried cannabis, and a 670-basis-point increase in adjusted gross margin. Like MedReleaf, Aphria is trying to grow its operations primarily through organic expansion. It's in the process of working on a multiphase expansion that'll boost its growing capacity to 1 million square feet. In fact, it recently upped its projected annual output to 100,000 kilograms once its $100 million phase 4 project is complete. As with the other producers above, this project couldn't come at a better time considering the rapid growth in registered medical patients and the possibility of legal recreational pot coming to Canada by next summer. Aphria is also among that aforementioned group of companies that have been given the OK to export cannabis to foreign countries. Between demand from Europe, Canada's medical pot industry, and the possibility of a recreational legalization, Aphria and its peers may struggle to meet demand, which would have been an almost laughable scenario just a few years before.